Cagrilintide peptide guide

Cagrilintide tells the brainstem you are full, then slows how fast food leaves your stomach. That is the same job natural amylin does after a meal, just stretched across a whole week instead of a few minutes.

At the receptor level, cagrilintide is a long-acting amylin analog that activates amylin receptors (AMY1R, AMY2R, AMY3R) and the calcitonin receptor in the hindbrain — placing it in a class sometimes called dual amylin and calcitonin receptor agonists, or DACRAs. Novo Nordisk's medicinal-chemistry team attached a C20 fatty diacid to lysine-1 to let the molecule bind albumin in blood, which extends the half-life from natural amylin's roughly 15 minutes to about 159 hours (around 7 days).

Because amylin and GLP-1 act through different brain regions and different receptors, the two pathways are complementary rather than redundant. That is the rationale behind CagriSema. The mechanism described here is supported by published preclinical and clinical pharmacology; long-term effects on appetite circuits beyond the 68-week trial window have not been studied.

The strongest evidence comes from the REDEFINE 1 trial (Garvey et al., NEJM, June 2025). REDEFINE 1 was a 68-week, Phase 3a, randomized, double-blind, placebo- and active-controlled trial in 3,417 adults with obesity or overweight plus a weight-related complication, and without type 2 diabetes. At week 68, mean body-weight change was about −20.4% with CagriSema versus −3.0% with placebo under the treatment-policy estimand, and roughly −22.7% under the trial-product estimand (the idealized scenario where all participants stayed on assigned treatment). About 60% of CagriSema participants reached at least 20% weight loss; about 23% reached 30% or more. I checked these specific figures against the Garvey et al. NEJM paper to keep the two estimands reported separately, because competitor pages frequently mix them.

REDEFINE 2 (Davies et al., NEJM, June 2025) ran the same regimen in 1,206 adults with obesity or overweight plus type 2 diabetes. Mean body-weight change at 68 weeks was −13.7% with CagriSema versus −3.4% with placebo, with 73.5% of CagriSema participants reaching HbA1c of 6.5% or less. Earlier data from the Phase 2 dose-finding trial (Lau et al., Lancet, 2021) showed cagrilintide 4.5 mg monotherapy produced about 10.8% weight loss at 26 weeks versus 3.0% with placebo, and cagrilintide 4.5 mg outperformed liraglutide 3.0 mg head-to-head. A February 2026 post-hoc analysis of the cagrilintide-monotherapy arm in REDEFINE 1 reported about 11.8% weight loss versus 2.3% with placebo at 68 weeks (Pharmacy Times coverage of Novo Nordisk readout, 2026).

Important limitations: the REDEFINE program is sponsor-funded by Novo Nordisk, and most of the body of evidence is concentrated in this one trial program. There is no head-to-head Phase 3 data versus tirzepatide. Long-term safety beyond 68 weeks is not yet published. Female participants are over-represented in REDEFINE 1, which has been raised in NEJM correspondence.

In the REDEFINE 1 trial, gastrointestinal adverse events were reported by 79.6% of CagriSema participants versus 39.9% of placebo (Garvey et al., NEJM, 2025). Most were transient and mild-to-moderate — nausea, vomiting, diarrhea, constipation, or abdominal pain. About 12% of CagriSema participants reported injection-site reactions in the same trial. In the Phase 2 monotherapy data, gastrointestinal events ranged 41–63% across cagrilintide doses versus 32% with placebo (Lau et al., Lancet, 2021). Cagrilintide monotherapy showed lower vomiting rates than semaglutide or liraglutide.

Theoretical concerns separate from observed events include thyroid C-cell tumor risk associated with the semaglutide component of CagriSema (a class-wide GLP-1 receptor agonist boxed-warning consideration) and pancreatitis, gallbladder, and kidney events at rates broadly similar to semaglutide monotherapy. Six deaths occurred across REDEFINE 1 and REDEFINE 2, all in CagriSema arms; an NEJM editorial flagged the suicide imbalance as warranting surveillance. CagriSema arms were roughly 3 times larger than placebo arms, which partly accounts for absolute imbalance.

As of April 2026, cagrilintide is investigational and not FDA-approved. CagriSema is not approved for any indication in the U.S. or EU. Novo Nordisk filed a New Drug Application on December 18, 2025 (FDA Docket / Drugs.com NDA tracking) based on REDEFINE 1 and REDEFINE 2. Standard FDA review timelines suggest a decision around October 2026. Standalone cagrilintide approval, if pursued, would follow on a separate regulatory track through the RENEW program.